Group Dialectical Behaviour Therapy (DBT) Skills Training for First Episode Psychosis
Group Dialectical Behaviour Therapy (DBT) Skills Training for Individuals With First Episode Psychosis: a Feasibility Study
Psychosis is a serious mental health condition that can affect how a person thinks, feels, and functions in daily life, often making it harder to maintain relationships, continue education, or work. Even with standard treatment, many people continue to experience emotional distress, depression, anxiety, and difficulty coping with strong emotions. These challenges can worsen recovery, increase the risk of substance use and suicidal behaviour, and place a significant burden on individuals, families, and the healthcare system.
Dialectical Behaviour Therapy (DBT) is a skills-based psychological treatment that helps people manage emotions, tolerate distress, and improve relationships. Although DBT has been effective in other mental health conditions, it has not been well studied in people with first-episode psychosis.
This study will evaluate an 8-week group DBT skills training adapted for individuals with first-episode psychosis. The study aims to assess whether the program is acceptable and feasible to deliver, and whether it may improve emotion regulation, mood, resilience, and functioning. Findings will inform whether a larger clinical trial of this intervention should be conducted.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Despite evidence that individuals with psychotic disorders experience marked emotion dysregulation, impulsivity and elevated suicide risk, they have largely been excluded from clinical trials evaluating DBT. Nevertheless, emerging pilot studies support the feasibility and potential efficacy of brief DBT-informed skills group in individuals with psychosis, with participants reporting high satisfaction and improvements in understanding and managing emotions, suicidality, and interpersonal functioning. However, this literature remains preliminary and underdeveloped, and no studies have evaluated group DBT skills intervention specifically for individuals with first-episode psychosis.
Aim 1: To evaluate the acceptability of the group DBT skills training invention and the feasibility of conducting a fully powered randomized controlled trial (RCT) of in young men with psychosis.
Aim 2: To assess the preliminary efficacy of group DBT skills training in improving emotion regulation, resilience, and functioning and reducing, mood and anxiety and substance use, in a single-arm exploratory clinical trial.
This study will provide evidence of the feasibility, acceptability, and preliminary efficacy of a group DBT skills training for young men with first-episode psychosis. Findings will advance understanding of emotion regulation as a treatment target in psychosis and inform the development of larger controlled trials evaluating emotion-focused interventions in early psychosis care. The intervention could represent a scalable and practical psychosocial treatment to address emotional difficulties that are common but often under-treated in psychosis.
This study employing qualitative and quantitative methods to evaluate the group DBT skills training intervention and test its feasibility, and acceptability in individuals with psychosis. A single arm trial where DBT skills group delivered over 8-weeks, will be conducted. Thirty-two participants are planned to be enrolled in the trial. Participants will continue with their standard outpatient care during the trial. Outcome measures will be completed at study entry and post-treatment. For the qualitative component of the study, 15 post-intervention semi-structured interviews will be conducted.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Omair Husain
- Numero di telefono: 36467 416-535-8501
- Email: omair.husain@camh.ca
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Bambino
- Adulto
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Be 14-35 years old.
- All gender identities are eligible to participate.
- Being competent as demonstrated by comprehension of the study procedures, risks, benefits and their rights as a volunteer in the research study and willing to consent to study participation.
- Meets criteria for a psychotic spectrum disorder as determined by Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (e.g., schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, delusional disorder, other specified schizophrenia spectrum disorder, or other unspecified schizophrenia spectrum disorder), or bipolar disorder with psychotic features, and is within 3 years of their initial diagnosis.
Exclusion Criteria:
- Diagnosis of intellectual disability previously documented in the patient chart.
- Acute suicidality requiring immediate life-saving intervention (i.e., inpatient psychiatric care).
- Receiving any additional structured psychotherapy interventions during the study period.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Group DBT
Receive 8-week Group DBT intervention
|
DBT skills group delivered over 8-weeks
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Adherence
Lasso di tempo: post treatment (8 weeks after baseline)
|
Percent sessions attended
|
post treatment (8 weeks after baseline)
|
|
Retention rates
Lasso di tempo: post treatment (8 weeks after baseline)
|
Percent participants who complete 8-week study.
|
post treatment (8 weeks after baseline)
|
|
Attrition
Lasso di tempo: post treatment (8 weeks after baseline)
|
Percent participants that dropout at 8 weeks
|
post treatment (8 weeks after baseline)
|
|
Client Satisfaction Questionnaire
Lasso di tempo: post treatment (8 weeks after baseline)
|
A Likert scale from 1-4, total scores range from 8-32, with higher scores indicating greater satisfaction.
|
post treatment (8 weeks after baseline)
|
|
Timeline Follow Back (TLFB)
Lasso di tempo: From enrollment to the end of treatment at 8 weeks
|
A self-report method for substance use, and will be used to quantify the amount/frequency of cannabis in the past 14 days.
|
From enrollment to the end of treatment at 8 weeks
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Brief Psychiatric Rating Scale (BPRS)
Lasso di tempo: From enrollment to the end of treatment at 8 weeks
|
a widely used instrument for the assessment of positive, negative and affective symptoms in individuals who have psychotic disorders.
It consists of 18 symptom constructs.
Total score range from 18-126, higher scores indicating higher severity.
|
From enrollment to the end of treatment at 8 weeks
|
|
Scale for the Assessment of Negative Symptoms (SANS)
Lasso di tempo: From enrollment to the end of treatment at 8 weeks
|
An instrument for measuring negative symptoms in schizophrenia.
It assesses five symptom complexes to obtain clinical ratings of negative symptoms in participants with schizophrenia.
They are: affective blunting; alogia (impoverished thinking); avolition/apathy; anhedonia/asociality; and disturbance of attention.
Assessments are conducted on a six-point scale (0=not at all to 5=severe).
Total score range from 0-110, higher scores indicating higher severity.
|
From enrollment to the end of treatment at 8 weeks
|
|
Calgary Depression Scale for Schizophrenia (CDSS)
Lasso di tempo: From enrollment to the end of treatment at 8 weeks
|
4-point Likert type scale (0, absent; 1, mild; 2, moderate; 3, severe) with nine items.
It is a reliable scale, with high internal consistency (Cronbach's alpha = 0.855), and the CDSS is suitable for evaluating symptoms of depression in people at clinical high risk for psychosis Total score range from 0-27, higher scores indicating higher severity.
|
From enrollment to the end of treatment at 8 weeks
|
|
State-Trait Anxiety Inventory (STAI)
Lasso di tempo: From enrollment to the end of treatment at 8 weeks
|
A psychological inventory consisting of 40 self-report items on a 4-point Likert scale.
The STAI measures two types of anxiety - state anxiety and trait anxiety.
Scores range from 20 to 80 for both state and trait anxiety, with higher scores indicating greater anxiety.
|
From enrollment to the end of treatment at 8 weeks
|
|
Borderline Symptom List (BSL-23)
Lasso di tempo: From enrollment to the end of treatment at 8 weeks
|
A well-established self-rating instrument to assess the severity of borderline typical psychopathology.
The BSL-23 assesses 23 feelings and experiences typically reported by BPD patients, refers to the last week and has a range from 0 = 'not at all' to 4 = 'very strong.
scores range from 0 to 92 with higher scores indicating greater symptom severity.
|
From enrollment to the end of treatment at 8 weeks
|
|
Difficulties in emotion regulation scale (DERS)
Lasso di tempo: From enrollment to the end of treatment at 8 weeks
|
A 36-item self-report measure of six facets of emotion regulation.
Items are rated on a scale of 1 ("almost never [0-10%]") to 5 ("almost always [91-100%]").
Scores range from 36 to 180, with higher scores indicating greater symptom severity.
|
From enrollment to the end of treatment at 8 weeks
|
|
Global Functioning: Social and Role Scales
Lasso di tempo: From enrollment to the end of treatment at 8 weeks
|
Brief clinician-administered measures of social and role functioning, respectively, administered as a semi-structured interview with detailed anchors for ratings that address functional difficulties typically experienced by youth at risk for psychosis.
Scores range from 1 to 10, with higher scores indicating greater functioning.
|
From enrollment to the end of treatment at 8 weeks
|
|
Connor-Davidson Resilience Scale (CD-RISC)
Lasso di tempo: From enrollment to the end of treatment at 8 weeks
|
A 25-item self-report rating scale designed to assess resilience, with higher scores being an indicator of high resilience.
Each item is rated on a 5-point scale ranging from not true at all or zero to true nearly all the time or four.
Scores range from 0 to 100, with higher scores indicating greater resilience.
|
From enrollment to the end of treatment at 8 weeks
|
|
Adolescent Alcohol and Drug Involvement Scale (AADIS)
Lasso di tempo: From enrollment to the end of treatment at 8 weeks
|
A clinician rated instrument which evaluates an adolescent's use of alcohol and other drugs.
The score is calculated from a weighted sum of item ratings on a scale of 1-12, where higher scores indicate more serious levels of involvement.
|
From enrollment to the end of treatment at 8 weeks
|
|
Cannabis Use Disorders Identification Test-Revised (CUDIT-R)
Lasso di tempo: From enrollment to the end of treatment at 8 weeks
|
A self-report tool developed that aim to distinguish between different levels of cannabis use, cannabis use disorders and stage of change.
It contains 8 items, two each from the domains of consumption, cannabis problems (abuse), dependence, and psychological features.
score range 0-32, more indicating hazardous cannabis use and scores of 12 or more suggesting a possible cannabis use disorder
|
From enrollment to the end of treatment at 8 weeks
|
|
Columbia-Suicide Severity Rating Scale (C-SSRS)
Lasso di tempo: From enrollment to the end of treatment at 8 weeks
|
A semi-structured clinical interview that assesses suicidal ideation severity, suicidal ideation intensity, and suicidal behavior.
intensity subscale (scored separately) that ranges from 0-25 by rating the frequency, duration, and controllability of ideation.
Overall Score 0: No suicidal risk Score 1-2: Low risk; safety planning recommended as a best practice Score 3-6: Moderate to high risk; requires safety planning and close follow-up
|
From enrollment to the end of treatment at 8 weeks
|
Collaboratori e investigatori
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 2026/060
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .